drugset
drugset / Trial / NCT02331498

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02331498 ↗

Phase 1/2 Active not recruiting 51 enrolled Centre Antoine Lacassagne GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)

Timeline

Start
2015-06
Primary completion
2027-02
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule — Oral

Indications

glioblastoma